Data / Drug companies / AstraZeneca AB
AstraZeneca AB: 39 products in the FDA NDC directory, labeler code 17228
AstraZeneca AB (labeler code 17228) lists 39 products in the FDA National Drug Code Directory. By type: 33 drugs for further processing, 6 bulk ingredients. Its main marketing category is drugs for further processing. The newest product started marketing on November 18, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 17228
- Products in commercial distribution
- 39
- Packages
- 41
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- September 14, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 33 | 84.6% |
| Bulk ingredients | 6 | 15.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 33 | 84.6% |
| Bulk ingredients | 6 | 15.4% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 13 | 33.3% |
| Tablet | 7 | 17.9% |
| Powder | 6 | 15.4% |
| Tablet, extended release | 4 | 10.3% |
| Capsule | 4 | 10.3% |
| Injection, solution | 3 | 7.7% |
| Tablet, delayed release | 2 | 5.1% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Baxdrostat | 17228-6002 | Tablet, film coated | Drugs for further processing | November 18, 2025 |
| Baxdrostat | 17228-6001 | Tablet, film coated | Drugs for further processing | November 18, 2025 |
| Selumetinib | 17228-0640 | Capsule | Drugs for further processing | September 10, 2025 |
| Selumetinib | 17228-0635 | Capsule | Drugs for further processing | September 10, 2025 |
| Capivasertib | 17228-9501 | Tablet, film coated | Drugs for further processing | November 10, 2023 |
| Capivasertib | 17228-9500 | Tablet, film coated | Drugs for further processing | November 10, 2023 |
| Budesonide micronised co-suspension apn | 17228-9700 | Powder | Bulk ingredients | March 9, 2023 |
| Albuterol sulfate micronised conditioned | 17228-9600 | Powder | Bulk ingredients | March 9, 2023 |
| Micronized glycopyrronium bromide | 17228-4610 | Powder | Bulk ingredients | November 7, 2022 |
| Micronized glycopyrronium bromide | 17228-5600 | Powder | Bulk ingredients | October 24, 2022 |
| Acalabrutinib | 17228-4512 | Tablet, film coated | Drugs for further processing | August 4, 2022 |
| Omeprazole magnesium | 17228-0750 | Tablet, delayed release | Drugs for further processing | February 16, 2022 |
| Benralizumab | 17228-2730 | Injection, solution | Drugs for further processing | December 15, 2021 |
| Olaparib | 17228-0668 | Tablet, film coated | Drugs for further processing | August 5, 2020 |
| Olaparib | 17228-0679 | Tablet, film coated | Drugs for further processing | August 4, 2020 |
| Dapagliflozin | 17228-6210 | Tablet, film coated | Drugs for further processing | May 5, 2020 |
| Dapagliflozin | 17228-6205 | Tablet, film coated | Drugs for further processing | May 5, 2020 |
| Durvalumab | 17228-4611 | Injection, solution | Drugs for further processing | January 1, 2020 |
| Durvalumab | 17228-4500 | Injection, solution | Drugs for further processing | January 1, 2020 |
| Osimertinib | 17228-1350 | Tablet, film coated | Drugs for further processing | November 13, 2015 |
| Osimertinib | 17228-1349 | Tablet, film coated | Drugs for further processing | November 13, 2015 |
| Ticagrelor | 17228-0776 | Tablet, film coated | Drugs for further processing | June 10, 2015 |
| Ticagrelor | 17228-7777 | Powder | Bulk ingredients | February 10, 2014 |
| Candesartan cilexetil hydrochlorothiazide | 17228-0324 | Tablet | Drugs for further processing | December 5, 2012 |
| Candesartan cilexetil hydrochlorothiazide | 17228-0322 | Tablet | Drugs for further processing | December 5, 2012 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.